Research programme: neurodegenerative disease therapeutics - ProMIS Neurosciences

Drug Profile

Research programme: neurodegenerative disease therapeutics - ProMIS Neurosciences

Alternative Names: PMN 330; PMN 350; PMN-310; TDP 43 targeting therapeutics

Latest Information Update: 24 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Amorfix Life Sciences
  • Developer ProMIS Neurosciences
  • Class Antidementias; Monoclonal antibodies; Neuroprotectants
  • Mechanism of Action Amyloid beta-protein modulators; Superoxide dismutase inhibitors; Tau protein inhibitors; TDP-43 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Neurodegenerative disorders

Highest Development Phases

  • Preclinical Alzheimer's disease; Amyotrophic lateral sclerosis; Dementia
  • Research Down syndrome

Most Recent Events

  • 19 Sep 2017 ProMIS Neurosciences plans a clinical trial for PMN 310 in Alzheimer's disease in 2019
  • 16 Jul 2017 Pharmacodynamics data from a preclinical trials in Alzheimer's disease presented at the (Alzheimer's Association International Conference 2017 (AAIC-2017)
  • 31 May 2017 Preclinical trials in Dementia in Canada (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top